Peregrine Pharmaceuticals (PPHM)
News
| May 29 | @BSB $PPHM Phase 2 results are good, stock still punished but good phase 3 results and nda filings will turn this ship around! by BiopharmaPro |
| May 25 | RT @HighGrowthFinancial after seeing $PPHM bounce today, $KVA is gettting some attention, downside shrinking by HighGrowthFinancial |
| May 25 | $PPHM With Robert Garnet leading the FDA approval process, this may be a huge winner. It was projected at $ 12 earlier this year. by BSB |
| May 24 | $PPHM stock receives no love yet shows good results. I think people are skeptical on Bavixtbaum. but it could prove to be ideal for cancer by BiopharmaPro |
| May 24 | @BiopharmaPro $PPHM is getting some press from bloggers like Wall ST Cheat ..I just like the bowl formation. IMO it hits 0.80 at the MA200. by Urbane_Gorilla |
| May 24 | @Urbane_Gorilla $PPHM is an under the radar stock! Good phase 2 results thus far. Once more come out and shows Bavi works ... will run!!! by BiopharmaPro |
| May 24 | only small cap pharm in my crosshairs today i didn't pull trigger on $PPHM ...hate chasin, waitin for .55 by HighGrowthFinancial |
| May 24 | $PPHM holding recent gains ok,called $KVA out off there strength few days ago,great companies now risky,Horrible companies working LONG by HighGrowthFinancial |
| May 22 | $PPHM Price fell in an instance and I believe the price can recover in an instance by FinantricALew |
| May 22 | $PPHM Looking for continuation. Phase III clinicals are in development. Promising company. http://stks.co/3vsq by FinantricALew |
| May 22 | Healthcare Stock Insights: Peregrine Pharma Explodes, J&J and the FDA |
| May 21 | PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements ... |
| May 21 | Chesapeake and 3 Super Hot Stocks Hitting Trader Radars Now |
| May 21 | MARKET PULSE: U.S. stocks on the move: Facebook, Radian, Cooper Industries |
| May 21 | Penn Virginia Corporation, Peregrine Pharmaceuticals Among Stocks Gapping Up Monday Fox Business |
Profile
Exchange: NASDAQCM Sector: Healthcare Industry: Biotechnology
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Peregrine Pharmaceuticals is down 74.16% over the last year vs S&P 500 Total Return up 0.88%, Cel-Sci Corporation down 31.43%, and Verastem up 7.61%.
- PPHM Total Returns
- ^SPXTR Total Returns
- CVM Total Returns
- VSTM Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these PPHM related companies
Pro Strategies Featuring PPHM
Did Peregrine Pharmaceuticals make it into our Pro Portfolio Strategies?
PPHM Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other PPHM Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PPHM | 0.5503 | +0.00 | +0.05% | 47.73M |
| PPH | 36.88 | -0.04 | -0.11% | |
| PPG | 103.39 | +1.13 | +1.11% | 15.60B |
| PPC | 8.21 | +0.13 | +1.61% | 1.733B |
| PPBI | 7.85 | -0.06 | -0.76% | 81.17M |
| PPA | 18.50 | -0.06 | -0.32% | |
| POZN | 6.91 | -0.11 | -1.57% | 210.46M |
| POWR | 4.14 | -0.16 | -3.72% | 81.31M |
| POWL | 36.78 | +0.01 | +0.03% | 432.05M |
| POWI | 40.76 | +0.13 | +0.32% | 1.149B |
